Vascular endothelial growth factor in inflammatory rheumatic diseases

Czech version

Authors: Zb. Hrnčíř; J. Tomš
Authors‘ workplace: Hradec Králové ; II. interní klinika, oddělení revmatologie a klinické farmakologie, Lékařská fakulta UK a Fakultní nemocnice
Published in: Čes. Revmatol., 17, 2009, No. 3, p. 168-172.
Category: Overview Reports

Overview

Vascular endothelial growth factor (VEGF) is a potent stimulating factor of angiogenesis (AG) and vascular permeability. VEGF exerts important physiological actions in embryogenesis, wound healing, and menstrual cycle. In pathological conditions, it has a significant role especially in solid tumour growth, but also in inflammatory disorders, incl. a broad spectrum of rheumatic diseases. High serum VEGF levels were especially observed in patients with an active form of these diseases (e.g. in systemic lupus erythematosus with correlation to SLAM score). VEGF has an important role in AG of proliferative synovitis in rheumatoid arthritis (RA), vascular changes in systemic sclerosis, and in local muscular hypoxia in polymyositis/dermatomyositis. In RA, incl. early RA, VEGF serum levels correlated with joint damage as shown in radiographic and power ultrasonography studies. Therapeutic response (DMARD, anti-TNF-alpha) in RA is associated with a decrease of elevated VEGF serum levels. Clinical experience in oncology, insights from a pathophysiology of rheumatoid synovitis, and from some experimental data suggest that AG blockade could be a possible novel strategy in RA therapy.

Key words:
vascular endothelial growth factor, angiogenesis, inflammatory rheumatic diseases, rheumatoid arthritis, systemic lupus erythematosus

Sources

1. Taylor PC. VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res 2002; 4 Suppl 3: S99–S107.

2. Naňka O, Grim M. Utváření cévního řečiště: přehled molekulárních mechanismů a možností terapeutického ovlivnění. Čas Lék čes 2009; 148: 158–63.

3. Koch AE. Angiogenesis. Implication for rheumatoid arthritis. Arthritis Rheum 1998; 41: 951–62.

4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 9: 669–76.

5. Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 2007; 27: 246–56.

6. Tian S, Chyou S. VEGF as potential mediator of antibody responses. Arthritis Rheum 2008; 58: S628.

7. Kasama T, Kobayashi K, Yajima N, et al. Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 121: 533–38.

8. Wauke K, Nagashima M, Ishiwata T, et al. Expression and localization of vascular endothelial growth factor-C in rheumatoid arthritis synovial tissue. J Rheumatol 2009; 29: 34–38.

9. Paavonen K, Mandelin J, Partasen T, et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol 2002; 29: 39–45.

10. Ikeda M, Hosoda Y, Hirose S, et al. Expression of vascular endothelial growth isoforms and their receptors flt-1, KDR, and neutrophillin-1 in synovial tissue of rheumatoid arthritis. J Pathol 2000; 191: 426–33.

11. Yoo SA, Yoon NJ, Kim HS, et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation. Arthritis Rheum 2009; 60: 345–54.

12. Harada M, Mitsuyama K, Yoshida H, et al. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377–80.

13. Lee SS, Joo YS, Kim WU, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 321–24.

14. Ballara S, Taylor PC, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055–64.

15. Nagashima M, Asaho G, Yoshino S. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 2339–42.

16. Hernandez GL, Volpert OV, Iniguez MA, et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001; 193: 607–20.

17. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenetic vascular endothelial growth factor (VEFG) by TNF-alfa and IL-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258–65.

18. Mould AW, Scotney P, Greco SA, et al. Prophylactic but not therapeutic activity of a monoclonal antibody that neutralizes the binding of VEGF-B to VEGFR-1 in a murine collagen-induced arthritis model. Rheumatology 2008; 47: 263–66.

19. Khong TL, Larsen H, Raats Y, et al. Angiogenesis as a therapeutic target in arthritis. Learning the lessons of the colorectal cancer experience. Angiogenesis 2007; 10: 243–58.

20. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophtalmol 2008; 92: 1035–39.

21. Kovach JL, Rosenfeld PJ. Bevacizumab (Avastin) therapy for idiopathic macular teleangiectasia type II. Retina 2009; 29: 27–32.

22. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Invest Drugs 2008; 9: 1324–35.

23. Kikuchi K, Kubo M, Kadono T, et al. Serum concentrations of vascular endothelial growth factor in collagen diseases. Brit J Dermat 1998; 139: 1049–51.

24. Robak E, Wozniacka A, Sysa-Jedrzejowska A, et al. Circulating angiogenesis inhibitor endostatin and positive endothelial growth factors in patients with systemic lupus erythematosus. Lupus 2002; 11: 348–55.

25. Avihingsanon Y, Phumesin P, Benjachat T, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring of lupus nephritis. Kidney Int 2006; 69: 747–53.

26. Hrncir Z, Drahosova M, Andrys C, et al. Angiogenetic growth factors in systemic lupus erythematosus with deforming arthropathy of small hand joints. Ann Rheum Dis 2009; 68 (suppl 1).

27. Distler O, Distler JWH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109–16.

28. Distler O, del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stage and are associated with the absence of finger ulcers. Arthritis Res 2002; 4 (6): R11.

29. Choi JJ, Min DJ, Cho ML, et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003; 30: 1529–33.

30. Grungtman C, Tham E, Ulfgren AK, et al. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum 2008; 58: 3224–38.

31. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 2005; 64: 1653–55.

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

Concomitant fibromyalgia in patients with rheumatoid arthritis

Rituximab in nephrologist’s hands – first experience

Treatment of patients with proximal femoral fractures. I. Orthopaedic care. Guidelines of the Czech Rheumatological Society and the Czech Society for Metabolic Bone Diseases

Safety of biological therapy – Guidelines of the Czech Society for Rheumatology

Current view on etiopathogenesis of fibromyalgia

Accelerated atherosclerosis in systemic lupus erythematosus

Article was published in

Czech Rheumatology

2009 Issue 3